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ABSTRACT  
Human pluripotent stem cells (hPSCs), including human embryonic stem cells 
(hESCs) and induced pluripotent stem cells (iPSCs) hold great promise in the fields of 
drug development and regenerative medicine. If iPSCs reprogrammed from patient cells 
replicate what is seen in vivo they may be used as a model of disease. A process that is 
disrupted in many neurodegenerative diseases is mitochondrial biogenesis. One of 
these diseases is amyotrophic lateral sclerosis (ALS), which is characterized by loss of 
motor neurons in the brain and spinal cord. Differentiation of hPSCs into motor neurons 
offers a way to study a previous unavailable cell type and may further our understanding 
of human motor neuron biology. The aims of the present study were to differentiate 
motor neurons from hESCs and iPSCs in low oxygen conditions and to explore 
mitochondrial biogenesis and electrical maturation during this process. After three 
weeks of treatment with retinoic acid and purmorphamine, a sonic hedgehog agonist, 
cells increased expression of post mitotic spinal motor neuron markers. One week later 
electrophysiological analysis revealed voltage-gated currents and action potential 
generation. Mitochondrial biogenesis signaling and expression of respiratory chain 
proteins increased with motor neuron differentiation. Respiration analysis revealed a 
decrease in glycolysis in motor neurons compared to neural stem cells. Interestingly, 
this was not accompanied by an increase in basal respiration or mitochondrial mass. 
These findings enhance our understanding of motor neuron mitochondrial biogenesis, a 
process impaired in ALS. 
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CHAPTER ONE: INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease 
characterized by loss of motor neurons in the brain and spinal cord. Despite extensive 
study, the mechanisms underlying the pathogenesis of sporadic ALS (sALS) are 
currently unknown. Recent studies in our laboratory and others have identified 
increased mitochondrial DNA (mtDNA) deletions, decreased electron transport chain 
(ETC) subunits, and decreased mitochondrial biogenesis (mitobiogenesis) signaling in 
post mortem tissue from sALS patients [1-5]. This bioenergetic impairment may provide 
evidence as to why motor neurons are specifically vulnerable in this disease. If ALS 
patient cells are unable to maintain a healthy population of mitochondria this could lead 
to mitochondrial dysfunction, decreased ATP production, and death of vulnerable cells 
like motor neurons. In order to study mitobiogenesis in human motor neurons, the 
current project uses human pluripotent stem cells (hPSCs) from healthy patients. The 
following chapter will review our current understanding of mitochondrial biogenesis 
signaling, differentiation of motor neurons in vivo and how we can replicate this in vitro 
in order to study the mechanisms underlying motor neuron death in ALS. 
 
1.1 Mitochondrial biogenesis  
Mitochondria play a role in many vital cell functions including ATP synthesis, 
calcium homeostasis, reactive oxygen species (ROS) production, and apoptosis. In high 
energy requiring post-mitotic tissues like brain, skeletal muscle, and heart, mitochondrial 
dysfunction is particularly damaging because cells cannot rid themselves of defective 
mitochondria by replicating. These cells rely on mitobiogenesis to produce mitochondrial 
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components, and mitophagy, fission and fusion as “quality control” mechanisms to 
maintain a population of functional mitochondria.  
 
1.1.1 Mitobiogenesis signaling 
Mitochondria are unique organelles in that they have their own genome. The 
double-stranded, circular mammalian mitochondrial genome encodes 13 proteins that 
are essential for respiratory chain function and oxidative phosphorylation, 2 rRNAs and 
22 tRNAs [6, 7]. Mitochondria are not self-sufficient, however, and rely on the nuclear 
genome to encode most of the ~1200-1500 proteins they require. Mitochondrial DNA 
(mtDNA) is particularly susceptible to damage by ROS because it has no histones, it is 
physically close to the respiratory chain where most ROS are generated, and 
mitochondria have only limited enzymes for repair of oxidatively damaged DNA. 
Deletions in mtDNA may arise from aberrant repair of oxidatively damaged mtDNA, 
have been found in tissues including the brain, skeletal muscle, and heart, and 
accumulate with age [8].  Low levels of these deletions would not be immediately 
harmful because cells have thousands of copies of mtDNA. However, with age or 
disease, mutations and deletions can accumulate [9, 10] and lead to decreased 
mitochondrial respiration and ATP production. Most mtDNA deletions and mutations are 
heteroplasmic, meaning the cell has a mixture of normal and mutated mitochondrial 
DNA, but mutations can be homoplasmic as well [11]. 
As depicted in Figure 1, mitobiogenesis is the process by which cells increase 
their mitochondrial components, which includes transcription of genes encoded by both 
the mitochondrial and nuclear genomes. Peroxisome proliferator-activated receptor 
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gamma, co-activator 1-α (PGC-1α) is an upstream regulator of transcription factors 
involved in mitobiogenesis and respiration including nuclear respiratory factors 1 and 2 
(NRF1, NRF2) and mitochondrial transcription factor A (TFAM) [12, 13].  For this reason 
PGC-1α is thought to be the ‘master regulator’ of mitobiogenesis. PGC-1α is regulated 
by chromatin remodeling [14, 15] as well as posttranslational modification [16]. PCG-1α 
interacts directly with NRF1 and 2 and estrogen-related receptor α (ERRα) which then 
translocate to the nucleus [17-19]. This results in an increased transcription of genes 
including those encoding ETC subunits and TFAM, which are then localized to the 
mitochondria [20]. TFAM is required for mtDNA maintenance and stimulates its 
bidirectional transcription [21]. A mitochondrial DNA-directed RNA polymerase 
(POLRMT) and mitochondrial DNA polymerase gamma (POLG) then perform mtDNA 
transcription and replication, respectively [22]. 
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Figure 1. Mitobiogenesis signaling. PGC-1α binds to NRF1/2 and ERRα,  
initiating gene expression of mitochondrial components  
 
 
 
 
 
 
 
 
 
 
 
  
5 
1.1.2 Mitobiogenesis in ALS 
 Mitochondrial dysfunction has been well characterized in a number of 
neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease, and 
ALS. ALS is characterized by loss of both upper motor neurons in the cerebral cortex 
and lower motor neurons in the brainstem and spinal cord. Death of lower motor 
neurons leads to progressive muscle weakness and atrophy with respiratory failure 
being the leading cause of death an average of three to five years after diagnosis [23, 
24]. ALS presents in late adulthood, is more common in men than women, and affects 
2-5 per 100,000 people worldwide [25]. Over 90% of cases have no family history of the 
disease, which thus occurs sporadically in most (sALS). 
Mitobiogenesis appears to be impaired in post mortem tissues of patients with 
sALS. PGC-1α and its downstream targets showed decreased expression in post 
mortem spinal cord and muscle from sALS patients [5]. Additionally, there was 
decreased activity of ETC subunits and increased mtDNA deletions in isolated post 
mortem spinal motor neurons [1-3] and skeletal muscle [4] of sALS patients. 
Mitochondrial encoded gene expression was significantly depressed in peripheral blood 
mononuclear cells (PBMCs) of sALS patients compared to neurologically healthy 
controls [26]. This suggests a systemic bioenergetic impairment. Interestingly, healthy 
human oculomotor neurons isolated from post mortem tissue showed increased gene 
expression related to mitochondrial function when compared to spinal motor neurons 
[27]. Upregulation of mitobiogenesis could be a protective mechanism and may be one 
reason why oculomotor neurons and PBMCs are spared in ALS. 
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The most widely studied form of ALS is the inherited form of the disease, familial 
ALS (fALS), which composes only 5-10% of all cases. The first genetic mutation 
associated with ALS was found in the enzyme Cu, Zn superoxide dismutase 1 (SOD1) 
and occurs in approximately 20% of fALS patients, less than 2% of total cases. Even 
less common genetic mutations known to cause ALS are in the RNA-binding proteins 
TAR DNA-binding protein 43 (TDP43) and fused in sarcoma (FUS), among many 
others. Recently, hexanucleotide repeats in the non-coding region of the C9ORF72 
gene was found to be responsible for approximately 22% of fALS cases and is present 
in 4% of sALS cases [28].  
A murine model has been created that expresses human mutant SOD1 at supra-
physiological levels. This model replicates some components of the disease, however it 
does not fully mimic the human disease condition. Much of our understanding of the 
mechanisms of ALS comes from studies using these mice, however translation of drugs 
and therapies identified by this model into patients has been disappointing. The only 
FDA approved treatment for ALS is riluzole; however, it was shown to only increase 
patient survival by two to three months and does not reverse progression of the disease 
[29]. 
 
1.2 Differentiation of motor neurons in vivo 
 There are unique signaling cascades during development that define the identity 
of every type of cell in the body. In order to make motor neurons in vitro we need to 
understand what normally happens during human development in vivo. 
 
  
7 
1.2.1 Signaling during development 
Spinal motor neurons are some of the most well characterized cell types in terms 
of their embryonic origin. Early in development the inner cell mass of the blastocyst 
specifies into the three germ layers: endoderm, ectoderm, and mesoderm. The 
patterning of the nervous system is due to repressing and activating signals from a 
multitude of transcription factors and other proteins [30]. This process is summarized in 
Figure 2, adapted from [31]. The dorsal portion of the ectoderm becomes the nervous 
system through inhibition of bone morphogenic proteins (BMPs) and activin signaling 
[32, 33]. After formation of the neural tube the hindbrain and spinal cord is specified 
from the forebrain and midbrain along the rostro-caudal axis by retinoic acid [34] (RA; 
Figure 2A). Following this, dorsoventral signaling specifies cell types [35] (Figure 2B). 
Motor neurons derive from the ventral portion of the neural tube and receive a high 
concentration of sonic hedgehog (SHH) signaling from the notochord and floor plate 
(FP). Opposing SHH is a concentration of BMP/TGFβ signaling from the roof plate. Also 
during this time RA is continuing to be released from somites [34]. These signaling 
gradients produce a grid-like order to the 5 progenitor domains of the spinal cord, V0-V3 
interneurons and motor neurons  (Figure 2B). SHH signaling activates homeodomain 
domain protein Nkx6.1, which induces transcription of MNR2, among others [30, 36]. 
MNR2 is a transcription factor is critical to the differentiation of motor neurons [36]. 
Following its expression cells exit the cell cycle and express Islet 1 and 2 (Isl1, Isl2) and 
the motor neuron specific transcription factor HB9 [30]. 
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Figure 2. Motor neuron specification in the developing embryo A) 
Motor neurons derive from the dorsal ectoderm in response to inhibition of 
BMP and activin signaling and retinoic acid B) BMP signaling from the roof 
plate (RP) opposes sonic hedgehog (SHH) signaling from the notochord 
(NC) and floor plate (FP). Retinoic acid (RA) is released from the somites 
(S). 
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1.2.2 Electrical properties of embryonic spinal motor neurons  
As motor neurons differentiate there is a dramatic change in passive membrane 
properties as well as an increase in soma size and neurite complexity. Passive 
membrane properties including input resistance and membrane time constant decrease 
during postnatal development of rat motor neurons [37]. Resting membrane potential 
becomes more hyperpolarized during late embryonic development of rat motor neurons 
[38] but then remains unchanged from neonatal to adult cells [37]. Membrane 
capacitance (Cm), an indicator of cell surface area, is increased during embryonic 
development of rat spinal motor neurons [39]. Many of these findings are replicated in 
motor neurons differentiated from human embryonic stem cells (hESCs). Input 
resistance, but not resting membrane potential, decreased [40] and soma size and 
complexity of neurite outgrowth increased during hESC-derived motor neuron 
maturation [40]. 
Voltage-gated ion channels are critical to proper motor neuron function. The 
major currents that underlie motor neuron resting membrane potential and action 
potential are sodium, potassium, and calcium currents. These currents are present at a 
very early stage in development and undergo changes during motor neuron maturation.  
All four voltage gated sodium channel subunits expressed in the central nervous 
system are also expressed in embryonic rat motor neurons, Nav1.1, 1.2, 1.3, and 1.6 
[41]. Previous studies in multiple animal models have identified that the upswing of the 
motor neuron action potential is underlay by the fast inactivating sodium current. The 
action potential is kept short by the fast inactivation of these channels and the necessity 
to return to the resting membrane potential before reactivation allows for a refractory 
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period in which another action potentials cannot be initiated. In this way recovery from 
inactivation of voltage gated sodium channels can control action potential firing 
frequency. Detailed activation and inactivation kinetics are difficult to study in motor 
neurons using voltage-clamp techniques. Due to their large size, the membrane takes 
more time to charge and extensive dendritic processes make it difficult to control the 
voltage of the cell (space clamp). 
Potassium currents play important roles in motor neuron resting membrane 
potential, action potential shape, and firing behavior.  Both transient (IA) and delayed 
rectifier (IK) potassium currents are seen in motor neurons in vivo [42] as well as in 
hESC-derived motor neurons [40]. These currents are responsible for the rapid 
repolarization of the membrane during an action potential. Potassium channels also 
underlie the afterhyperpolarization (AHP), a period of membrane hyperpolarization that 
occurs after an action potential is generated. The AHP can be broken down into fast, 
medium, and slow components. Large conductance (BK) and small conductance (SK) 
calcium-activated potassium channels underlie the fast and medium components of the 
AHP, respectively. It is unknown what channels underlie the slow AHP, but previous 
studies implicate potassium channels in the KCNQ family [43]. 
In isolated chick motor neurons there were slightly more sodium currents than 
potassium currents (~70 pA/pF compared to ~60 pA/pF)[44]. From E4-E11 sodium 
current density increased 60% and correlated with increased action potential amplitude. 
During this time there was a large increase (16 fold) in IA and a small (25%) increase in 
IK. The increase in IA resulted in a shortening of action potential duration with motor 
neuron maturation[44]. Calcium currents matured last, with L- and N- type currents 
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increasing slightly during E4-11 and T-type currents decreasing[45]. Calcium currents 
were very small compared to sodium currents, and the fact that TTX blocked action 
potential generation suggests that action potential generation is sodium channel 
dependent during this time period.  
 
1.3 Intrinsic susceptibility of motor neurons 
Alpha (α)-motor neurons are selectively vulnerable in ALS, with fast fatigable 
(FF) motor units degenerating faster than slow (S) motor units [46]. Interestingly, there 
are two populations of motor neurons that are spared in the disease. Motor neurons in 
Onuf’s nucleus in the sacral section of the spinal cord that control voluntary bladder and 
rectal sphincters, and oculomotor nuclei in the brainstem that control voluntary eye 
movements are spared in both sporadic and genetic forms of ALS [27]. It is unknown 
why only specific cell types, even within the motor neuron population, are lost in this 
disease. However, by looking at the properties that distinguish these cells from other 
cell types may give us insights into why they are more vulnerable.  
 
1.3.1 Calcium buffering 
Control of motor neuron excitability is vital to optimal development of sustained 
muscle contractions [47]. Calcium is a second messenger in many signaling cascades 
and plays an important role in the repetitive firing properties of motor neurons. An 
increase in calcium depolarizes the cell and makes it more likely to fire action 
potential(s). However, increased intracellular calcium could lead to greater reliance on 
mitochondria to buffer calcium and therefore exacerbate mitochondrial damage caused 
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by normal aging. Combined with a genetic susceptibility to ALS and/or environmental 
factors this could lead to ALS pathology. 
Motor neurons are predicted to have problems handling large amounts of calcium 
because of their low content of calcium buffering molecules such as calbindin-D2sK and 
parvalbumin [48], and their large size [49]. For this reason, they rely on intracellular 
organelles like mitochondria to take up excess calcium. Previous studies using rat and 
mouse spinal motor neurons in vitro revealed an increased reliance on mitochondria to 
buffer calcium as compared to other neuron types [50, 51]. In brainstem slices from 
mice mitochondrial dysfunction induced by blocking complex IV of the ETC or 
uncoupling ATP synthesis resulted in increased intracellular calcium and excitability of 
motor neurons [52]. Because mitochondria accumulate cytosolic calcium mainly in a 
membrane potential (ΔψM)-dependent manner through the calcium uniporter, 
bioenergetic impairments and/or excessive “leak” of protons across a damaged inner 
membrane are predicted to lower ΔψM and reduce mitochondrial calcium buffering. 
Unfortunately, mitochondria show a decline in bioenergetic function with age and 
disease. Therefore, aging itself may contribute to motor neuron death due to a reduced 
capacity for calcium buffering leading to calcium-mediated activation of cell death 
signaling. 
Motor neurons also have a large number of calcium permeable glutamate 
receptors. Glutamate is an excitatory neurotransmitter and an increase in glutamate 
leads to an influx of sodium and calcium into the cell. One type of ionotrophic glutamate 
receptors is the α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor. 
Normally pre-mRNA for the GluA2 subunit of the AMPA receptor is edited by adenosine 
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deaminase acting on RNA 2 (ADAR2) at a specific site, converting adenosine to 
inosine. During translation, this site is read as an arginine (R) instead of a glutamine 
(Q). AMPA receptors containing the edited GluA2 subunit conduct mainly sodium; 
however the lack of this subunit or improper editing allows the channel to conduct 
calcium as well. Human spinal motor neurons contain a large number of calcium 
permeable AMPA receptors that lack the GluA2 subunit when compared to other neuron 
types [53, 54]. Additionally, human oculomotor neurons showed increased expression of 
the GluR2 subunit compared to spinal motor neurons [27]. Additionally, increased 
glutamate has been found in the cerebral spinal fluid of sALS patients [55]. This may be 
explained by loss of the glial glutamate transporter EAAT2 in spinal cord and motor 
cortex of sALS post mortem tissue [56]. EAAT2, predominately expressed in astrocytes, 
allows for the uptake of excess glutamate in the extracellular space. 
Motor neurons are also unique in their expression of voltage gated calcium 
channels. They express both high-voltage-activated and low-voltage-activated calcium 
channels that play a role in action potential duration [42]. High-voltage-activated L-type 
channels, specifically subtype Cav1.3, have been shown to mediate the persistent 
inward current (PIC) that underlies plateau potentials in spinal motor neurons [57, 58]. 
Cav1.3 channels open at approximately -55 mV, near the resting membrane potential 
and 20 mV below the other L-type calcium channel expressed in the mammalian 
nervous system, Cav1.2 [59]. This allows calcium influx even at rest or with small 
depolarizations. In mice there is low expression of Cav1.3 in spinal motor neurons at 
birth but expression increases as motor neurons mature, reaching adult levels by 
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postnatal day 18 [57, 60]. The expression of Cav1.3 channels in human motor neurons 
has not been studied.  
 
1.3.2 Plateau potentials  
Another property of motor neurons is the ability to generate plateau potentials. 
Plateau potentials are characterized by sustained membrane depolarizations after a 
stimulus has been terminated. Plateau potentials are activated by excitatory synaptic 
input or membrane depolarization, which then activates PICs of calcium and sodium. 
PICs act to amplify incoming signals [61-63]. The sodium PIC is activated quickly but 
quickly inactivates, and plays an important role in initiating action potentials during 
repetitive firing [61, 62, 64]. The calcium PIC activates slowly but is persistent and 
increases in amplitude with repeated excitatory stimulation [62, 65].  
 
1.3.3 Repetitive firing  
Increased intracellular sodium and calcium and/or a decreased potassium results 
in a cell that is more likely to fire action potentials. The generation of repetitive action 
potential firing in response to a sustained stimulus is a characteristic of mature motor 
neurons. Repetitive firing is modulated by the afterhyperpolarization (AHP). AHP is a 
period of hyperpolarization after an action potential is fired in which the neuron’s 
membrane potential is lower than normal, inhibiting further action potentials. The AHP 
can be broken down into fast, medium and slow components (fAHP, mAHP, and sAHP). 
It is unknown exactly which channels underlie the sAHP, but voltage-gated potassium 
channels in the KCNQ family have been implicated. Large (BK) and small conductance 
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calcium-activated potassium (SK) channels underlie the fAHP and mAHP, respectively. 
When these channels are opened by calcium binding, they allow the efflux of 
potassium, repolarizing the cell. An increase in SK channel conductance would result in 
fewer action potentials, while a decrease would result in repetitive firing of action 
potentials. Motor neurons rely heavily on these channels to mediate the proper balance 
of repetitive firing.  
Lengthening the AHP after an action potential is fired, by activating SK channels, 
may be beneficial to hyperexcitable motor neurons in sALS patients. Additionally, SK 
channel activation would result in decreased intracellular calcium through negative 
feedback on NMDA receptors. When glutamate binds NMDA receptors there is no influx 
of calcium until there is membrane depolarization, relieving a magnesium block of the 
channel. When this happens, an increase in intracellular calcium activates SK channels, 
potassium effluxes, and the membrane repolarizes. Riluzole, the only FDA-approved 
treatment for ALS, decreases the excitable neurotransmitters glutamate and sodium in 
the synapse [66]. A recent study suggests that riluzole activates SK channels as well 
[67]. The fact that riluzole has many targets may explain why it is not more effective in 
treating ALS. If we were able to determine which mechanism(s) of action were most 
beneficial for motor neuron survival, we may be able to develop improved drugs that 
have less unintended activity.  
Another current that underlies bursts of action potentials is the hyperpolarization-
activated current (Ih). Channels that underlie Ih are permeable to both sodium and 
potassium and Ih acts to return the membrane back to resting after being hyperpolarized 
[37]. Ih increases with postnatal maturation and underlies rebound depolarizations. This 
  
16 
current may play a role in rebound bursts of action potential firing seen after inhibitory 
synaptic input in both native and hESC-derived motor neurons [40, 42]. 
 
 
1.3.4 Properties altered in ALS 
Hyperexcitability has been seen in ALS patients [68-70] and in a mouse model of 
ALS [71, 72]. In mice, hyperexcitability is one of the earliest phenotypes, occurring long 
before symptom onset, and appears to be due to active rather than passive membrane 
properties. There was no change in the resting membrane potential, input resistance, 
action potential duration, amplitude, or threshold, or in afterhyperpolarization between 
mice carrying a G93A mutation in SOD1 and controls [71, 72]. There was, however, a 
significant increase in action potential firing frequency and the amount of current 
necessary to fire an action potential (rheobase) in the mutant mice [71-73]. This 
increase in excitability could be due to a number of factors, including increased inward 
and/or decreased outward currents.  
In ALS patients there is evidence for an imbalance of sodium and potassium 
channels [74, 75]. Increased sodium conductance was seen in motor neurons from 
fALS patients. In contrast, one study found a decrease in the voltage gated potassium 
channel Kv1.2 was found in the ventral roots of sALS patients but no change in sodium 
channels [76]. Alteration in sodium and potassium currents is also seen in the SOD1 
mouse model. Motor neurons from SOD1 mutant mice show increases in both sodium 
and calcium PICs and develop mature action potentials faster than their wild-type 
counterparts [66]. Isolated embryonic motor neurons from SOD1 mutant mice show 
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increased recovery from fast inactivation of voltage gated sodium channels when 
compared to mice expressing normal human SOD1 and wild type mice [77]. This could 
decrease the refractory period after an action potential is fired, leading to an increase in 
firing rates. 
 
1.4 hPSCs 
The classification of human pluripotent stem cells (hPSCs) includes both human 
embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). hESCs are 
derived from the inner cell mass of a pre-implantation blastocyst [78]. These cells can 
divide indefinitely while remaining pluripotent, or can be differentiated into any cell type 
in the body. Initially there was much hope for hESCs in disease modeling and cell 
replacement therapies. However, ethical issues and transplantation rejection concerns 
have limited their use in humans. iPSCs, on the other hand, could be derived from the 
patients’ own cells and therefore have the same genetic background. This would be 
particularly important for modeling complex diseases like ALS in which there is no one 
gene mutation that causes the disease. If motor neurons derived from ALS patient 
iPSCs replicate features seen in the disease they may be useful for understanding ALS 
pathology and testing therapies. 
 
1.4.1 Reprogramming of somatic cells 
 Initial reprogramming studies found that somatic cells could be reprogrammed 
into pluripotent cells by nuclear transfer into oocytes [79] or by fusion with ESCs [80, 
81]. This suggests that there are soluble factors that determine pluripotency. In 2006 
  
18 
retroviral transduction of four transcription factors, Oct3/4, Sox2, c-Myc, and Klf4, was 
sufficient to induce reprogramming of mouse fibroblasts [82]. The next year the same 
was found for human fibroblasts [83]. Since then other cells have been reprogrammed 
including blood cells [84, 85].  
 Although integration of foreign DNA is efficient at reprogramming somatic cells, 
these types of cells would not be safe for clinical use because of their potential for DNA 
mutations. To address this issue many protocols have been developed to deliver 
recombinant proteins or mRNA. However, the efficiency of reprogramming using these 
methods is extremely low and the proteins must be delivered multiple times for a period 
of several weeks. Another option is to express the reprogramming factors using a non-
integrating plasmid. The latent origin of plasmid replication (oriP) and one viral protein, 
Epstein-Barr Nuclear Antigen 1 (EBNA1) from the Epstein-Barr virus has been shown to 
be sufficient for replication of the viral plasmid [86] and adding these elements to a 
plasmid containing four reprogramming factors allows their expression without DNA 
integration. Expression of the Simian virus 40 (SV40) large T antigen allows for 
enhanced reprogramming efficiency and the foreign DNA is spontaneously lost after 10-
12 passages [87-89]. It is unknown exactly how expression of the SV40 T antigen 
increases reprogramming efficiency, however it may act to increase transcription 
replication of the plasmid. This plasmid system has been used to reprogram human 
peripheral blood mononuclear cells (PBMCs) with a single transfection in as little as 14 
days and the epigenetic profile of iPSCs derived from PBMCs shows promoter DNA 
methylation status more similar to human ES cells than iPSCs derived from fibroblasts 
[89]. In 2012 a protocol was described that increases the efficiency of PBMC 
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reprogramming with an improved EBNA1/OriP-based plasmid expressing five 
reprogramming factors (Oct4, Sox2, Klf4, c-Myc, and Lin28) as a single unit separated 
by 2A peptide sequences which allows for the co-translational cleavage into individual 
peptides [90].  PBMCs isolated from as little as five milliliters of peripheral blood can be 
used fresh or after freezing and lymphocytes are eliminated before reprogramming to 
reduce the chance of somatic recombination found in T lymphocytes [90]. In addition to 
having a favorable epigenetic profile after reprogramming, PBMCs are less invasive to 
obtain than fibroblasts, and are exposed to fewer environmental mutagens. Also, 
PBMCs need less time in culture before reprogramming and generate colonies faster 
after reprogramming than fibroblasts [89]. 
 
1.4.2 Using iPSCs to study ALS 
The reprogramming of fibroblasts from patients with fALS with a mutation in 
SOD1 into iPSC and subsequent motor neuron differentiation was first reported in 2008 
[91]. Since then many types of fALS have been modeled using iPSCs from patient 
fibroblasts including TDP43 [92, 93], C9ORF72 [94, 95], and vamp-associated protein 
B/C (VAPB)[96]. Only one study to date has used iPSCs from sALS patients [97]. All of 
these studies describe the chemical characteristics of iPSC derived motor neurons, 
including immunostaining for the motor neuron transcription factors HB9 and Islet1, 
followed by expression of choline acetyltransferase (ChAT). Many also show functional 
characterization of ion channel and action potential formation by whole cell patch clamp. 
There are data to suggest that these cells retain disease-causing mutations 
during reprogramming and display a phenotype similar to what is seen in patients. 
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Motor neurons differentiated from patient iPSCs with mutations in TDP43 conserved 
genetic mutations and increased vulnerability to cell stress [92, 93].  
Recent findings suggest that iPSCs from fALS patients show some of the same 
characteristics of intrinsic hyperexcitability seen in the disease. ALS iPSC-derived motor 
neurons with mutations in three different genes displayed increased spontaneous firing 
when compared to healthy or isogenic controls [98]. Upon further investigation the 
authors found decreased magnitude of delayed-rectifier potassium currents but no 
change in sodium currents. Treatment with retigabine, an activator of delayed-rectifier 
potassium channels, decreased spontaneous firing and increased survival of ALS 
patient derived motor neurons [98]. 
Another study found that motor neurons derived from ALS patients with a 
hexanucleotide repeat in C9ORF72 are more susceptible to glutamate toxicity. This 
could be rescued by antisense oligonucleotides targeting C9ORF72 or by knockdown of 
an RNA binding protein, ADARB2. ADAR proteins mediate editing of the GluR2 AMPA 
receptor, making it calcium impermeable. Without this editing, as happens in sALS [99], 
AMPA receptors are calcium permeable and may contribute to excitotoxicity [95]. 
 
1.4.3 Mitochondrial regulation in hPSCs 
 
Respiration analysis suggests that hPSCs produce the majority of ATP through 
anaerobic glycolysis compared to mitochondrial oxidative phosphorylation (OXPHOS) in 
somatic cells [100-103]. The details of this reversible switch remain unclear, and may 
vary between different cell lineages. Initial studies reported that hPSCs had few, 
underdeveloped mitochondria [104-106]. Recent studies have shown that while they 
rely on glycolysis for ATP production, hPSCs have active respiratory chain complexes 
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and respire at maximal capacity [100, 107]. Glycolysis is not as efficient at making 
energy but is faster and produces less ROS than OXPHOS. The switch to OXPHOS 
during differentiation would require increased mitochondrial respiratory capacity. There 
is evidence to suggest that this is achieved by an increase in mitochondrial mass, ATP 
and subsequent ROS production during spontaneous differentiation of hPSCs [108, 
109]. This process is reversed during reprogramming of somatic cells into iPSCs. 
Recent studies have started to shed light on the mechanisms underlying the 
switch from glycolysis to OXPHOS during cellular differentiation. One protein thought to 
be involved in this switch is uncoupling protein 2 (UCP2). UCP2 is a mitochondrial 
protein located in the inner membrane and is thought to uncouple the ETC from the 
production of ATP by allowing protons to leak through the membrane. The exact 
function of UCP2 remains unknown but recent findings implicate it in the metabolic 
change from glycolysis to OXPHOS during cellular differentiation by decreasing glucose 
utilization by mitochondria [110, 111].  UCP2 expression decreased during neuronal 
differentiation of mouse embryonic stem cells [112]. Hypoxia-inducible factor one alpha 
(HIF1α) is another protein that appears to be important for iPSC reprogramming. A 
recent study found increased HIF1α in undifferentiated cells and activation of HIF1α 
resulted in increased glycolysis and improved reprogramming [113]. 
 
1.4.4 Low oxygen conditions  
Normal cell culture conditions grow cells in room air containing approximately 
20% oxygen. This is much higher than what cells are exposed to in the developing or 
adult nervous system. Interstitial tissue oxygen levels in the mammalian brain range 
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from ~1-5% [114]. Low oxygen conditions (2-5%) have been shown to enhance 
proliferation, differentiation and survival of stem cells and neurons [115-118], including 
spinal motor neurons [117]. No ALS iPSC studies to date have used low oxygen 
conditions. 
 
1.5 Aims of the study 
The hypothesis to be tested in the current study states that differentiation of 
human pluripotent stem cells into electrically excitable motor neurons will result in 
increased mitochondrial biogenesis. 
 
The specific aims are: 
1. To generate motor neurons from hESC- and iPSC-derived human neural stem 
cells 
2. To determine the effect of motor neuron differentiation on mitobiogenesis in 
human neural stem cells in 5% oxygen conditions 
3. To examine the electrophysiological maturation of hPSC-derived motor neurons  
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CHAPTER TWO 
GENERAL METHODS 
 
2.1 Culture of hESC-derived hNSCs 
GIBCO® Human Neural Stem Cells were purchased from Life Technologies 
(Grand Island, NY). These cells are derived from the NIH approved human embryonic 
stem cell line H9 (WA09) and retain a normal human female karyotype for multiple 
passages. They can be differentiated into neurons, oligodendrocytes, or astrocytes. To 
remain in an undifferentiated state cells were grown in KnockOut D-MEM/F-12 
containing 2 mM GlutaMAX-I supplement, 20 ng/mL human recombinant basic 
fibroblast growth factor (bFGF) and epidermal growth factor (EGF) and 2% StemPro 
neural supplement up to passage 32. Medium was changed every 2-3 days and cells 
were maintained between 50 and 90% confluence. When cells were ~90% confluent 
they were dissociated using TrypLE™ and plated on culture vessels coated with 
CELLStart™. All cultures were grown at 37°C in 5% oxygen and 5% CO2 conditions. 
 
2.2 iPSC generation and neural induction 
Peripheral blood was collected from one healthy male control patient, age 62, in 
accordance with a Virginia Commonwealth University IRB-approved protocol at the 
Parkinson’s and Movements Disorder’s Center. Integration-free iPSCs were generated 
from human peripheral blood mononuclear cells (PBMCs) using a previously described 
protocol[90], with modifications. Specifically, blood was collected in sodium citrate 
vacutainers and PBMCs were isolated using Ficoll-Paque Premium (GE Healthcare) 
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density gradient centrifugation within 4 hours of draw time. PBMCs were expanded by 
culturing for two weeks in PBMC medium that supports erythroblast expansion and 
eliminates lymphocytes.  Lymphocytes were not used for reprogramming because of 
their high incidence of somatic rearrangements. The pEB-C5 and pEB-Tg plasmids 
were obtained from Addgene (Cambridge, MA) and grown in the VCU Macromolecular 
Core Lab.  The pEB-C5 plasmid contains five reprogramming factors (OCT4, SOX2, 
KLF4, c-MYC, and Lin28) and the pEB-Tg plasmid contains the SV40 large T antigen 
that enhances reprogramming efficiency. 3x106 PBMC were electroporated with the 
plasmids using an Amaxa Nucleofector 4D (Lonza, Allendale, NJ).  This technique uses 
electrical pulses to permeabilize the cell membrane in order to allow the plasmid access 
to the cytosol. Immediately following electroporation an equal volume of 37 °C RPMI 
medium was added to the cuvette and the cells allowed to recover for 10 min at 37 °C 
before returning to culture in PBMC medium. Transfected cells were co-cultured on 
mouse embryonic fibroblasts beginning at day 2 and the schedule of medium changes 
outlined in the protocol were followed.  On day 14 maintenance medium was changed 
to mTeSr (Stem Cell Technologies, Vancouver, BC) and colonies with PSC morphology 
were picked to wells of a 96 well plate beginning at about day 21.  Viable colonies were 
expanded in mTeSR medium on Geltrex (Life Technologies, Grand Island, NY) coated 
plates at 37° C in a humidified CO2 incubator with the oxygen level held at 5%. Growth 
medium supplemented with 10 uM ROCK inhibitor Y27632 (R&D Systems, Minneapolis, 
MN) was used for the first 24 hours after colonies were split.  
Neuralization of iPSCs was accomplished using PSC Neural Induction Medium 
(Life Technologies) according to protocol [119] with modifications.  This protocol allowed 
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for a faster, less labor-intensive, and consistent neural induction protocol. Briefly, iPSC 
colonies were maintained in PSC Neural Induction Medium beginning at day 1 after 
splitting.  On day 5 colonies with good morphology were picked to fresh Geltrex coated 
dishes and induction continued for another 5 days.  On day 10 colonies were detached 
using Accutase (Life Technologies), passed through a 100 um strainer, centrifuged at 
300 x g for 4 min. and plated in neural expansion medium on Geltrex coated dishes.  
Cultures were maintained at 37° C in a humidified CO2 incubator with the oxygen level 
held at 5%.   Growth medium supplemented with 10 uM ROCK inhibitor Y27632 (R&D 
Systems, Minneapolis, MN) was used for the first 24 hours after the neural stem cells 
were split through passage 4. 
 
2.3 Differentiation of hNSCs into motor neurons 
For differentiation of hESC-derived hNSCs into motor neurons media was 
changed to neurobasal medium containing 2% B-27 serum-free supplement and 2 mM 
GlutaMAX-I supplement plus 0.1 µM retinoic acid (RA) for 7 days followed by 7-21 days 
of 0.1 µM RA plus 0.5 µM purmorphamine (PM) [117, 120-126]. Media was changed 
every 2-3 days and cultures received half media changes except on days 0 and 7, when 
cultures received full media changes. RA and PM concentrations and timing were 
chosen based on previous studies [120, 127].  
After neural induction, iPSCs were differentiated as described previously, with 
some modifications [128]. Briefly, adherent cells were grown in neural induction media 
containing DMEM/F12 with 0.2 µM LDN-193189 (LDN; Stemgent), 10 µM SB431542 
(SB; Stemgent), 10 ng/ml BDNF (R&D systems), 0.4 ug/ml L-ascorbic acid (Sigma), 2 
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mM GlutaMAX-I supplement, 1% N-2 supplement, and 1% nonessential amino acids 
(NEAA). Two days later 1 µM RA was added. On day four LDN/SB was stopped and 1 
µM smoothened agonist (SAG; Calbiochem or Santa Cruz) and 0.5 µM PM were added. 
On day 14 cells were switched to neurobasal media containing 2 mM GlutaMAX-I, 2% 
B-27, 1% NEAA, 0.4 ug/ml AA, 10 ng/ml GDNF (R&D), 10 ng/ml CNTF (R&D). Media 
was replaced every 2-3 days. Unless otherwise specified, all cell culture materials were 
purchased from Life Technologies. All cultures were grown at 37°C in 5% oxygen and 
5% CO2 conditions. 
 
2.4 Nucleic acid isolation and cDNA synthesis 
For qPCR analysis of hESC-derived cells DNA and RNA were extracted at 
seven-day time points through day 28 using the AllPrep DNA/RNA Mini Kit (Qiagen) 
according to manufacturer instructions. In order to achieve increased yield and quality, 
for iPSC-derived cells RNA was extracted at D0 and D21 with the RNeasy or RNeasy 
Plus Micro Kit (Qiagen) and DNA was extracted with the DNeasy Blood and Tissue Kit 
(Qiagen) according to manufacturer instructions. Quantification of isolated DNA and 
RNA was performed using a Nanodrop 2000c spectrophotometer (Thermo Scientific). 
RNA was reverse transcribed into cDNA using the iScript or iScript Advanced cDNA 
synthesis kit (BioRad) which uses both random hexamer and oligo dT primers, following 
the manufacturer’s protocol.  
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2.5 Quantitative PCR 
For qPCR, 25-50 ng cDNA or 0.1 ng of DNA per well was loaded into a 96-well 
plate and analyzed with the CFX-96 Real-Time PCR Detection System (BioRad) using 
relative quantitation methods. All samples were analyzed in triplicate. Neuronal markers 
(NEFL, MAP2, and TUBB3), TFMB2, and mtDNA-encoded genes (12s rRNA, ND2, 
CO3, ND4) were measured using a multiplex qPCR assay. Endogenous reference 
genes (TOPO1, 14-3-3-Z, GAPDH, B2M, CYC1, AND UBC), pluripotency genes (KLF4, 
CMYC, LIN28, OCT4, SOX2) mitochondrial biogenesis genes (PGC-1α, POLG, 
POLRMT, TFAM, ERRα, NRF1, NRF2), glial markers (GL1-1 and GFAP), NSE was 
measured individually using EvaGreen PCR. Primers for PGC-1α were specifically 
designed in a region to detect all major isoforms. Primer sequences can be found in 
Figure 3. Reagents included SsoFast EvaGreen® Supermix (BioRad) and primers 
designed with Beacon Designer software (Premier Biosoft international, Palo Alto, CA) 
and supplied by Eurofins MW Operon (Huntsville, AL). PCR conditions were 30 seconds 
at 95 °C, followed by 40-45 cycles of 10 seconds at 95 °C and then 15 seconds at Tm 
(primers) -5 °C. Melt curve analysis was used to verify primer specificity, and efficiency 
was determined using standard curve analysis of commercially available human fetal 
brain total RNA (Clontech, Mountain View, CA).  
All gene expression analysis were conducted using the qbasePLUS® relative 
quantitation method (Biogazelle qbasePLUS®, http://www.biogazelle.com), which is a 
modification of the ΔΔCq method that allows normalization with multiple reference 
genes. Data was normalized to the geometric mean of two reference genes determined 
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to have the greatest stability using the software qbasePLUS-GeNorm (BioGazelle; 
14.3.3.Z and CYC1 for cDNA and CYC1 and GAPDH for gDNA for both cell types). 
 
MtDNA encoded genes 
ND2  PROBE [6-FAM]CACGCAAGCAACCGCATCCATAAT[BHQ1a-Q] 
ND2  SP AAGCTGCCATCAAGTATTTCC 
ND2   ASP GTAGTATTGGTTATGGTTCATTGTC 
      
COX3  PROBE [5TET]CGAAGCCGCCGCCTGATACTG[BHQ1a-Q] 
COX3  SP TTTCACTTTACATCCAAACATCAC 
COX3  ASP CAATAGATGGAGACATACAGAAATAG 
      
ND4  PROBE 
[AminoC6+TxRed]AGCCAGAACGCCTGAACGCAG[BHQ2a-
Q] 
ND4  SP TGGCTATCATCACCCGATG 
ND4  ASP GGTGTTGTGAGTGTAAATTAGTC 
      
12SrRNA PROBE [Cy5]CGCCAGAACACTACGAGCCACAG[BHQ3a-Q] 
12SrRNA SP CCTCAACAGTTAAATCAACAAAAC 
12SrRNA ASP CTGAGCAAGAGGTGGTGAC 
 
Mitobiogenesis genes 
POLg SP TGGTCAAACCCATTTCACTG 
  ASP AGAACACCTGGCTTTGGG 
      
ERRa SP CTTCGCTCCTCCTCTCATC 
  ASP CTGGAGTCTGCTTGGAGTTAT 
      
NRF1 SP TTTGTATGCCTTTGAAGAT 
  ASP AACCTGGATAAGTGAGAC 
      
NRF2 SP GTTACAACTAGATGAAGAGACA 
  ASP ATCCACTGGTTTCTGACT 
      
TFAM SP AATCTGTCTGACTCTGAA 
  ASP CACATCTCAATCTTCTACTT 
      
TFMB2 SP GTATCTTATTCAAATGATTCCTC 
  ASP TAAGTGGTCTATTACAGTGG 
  Probe [5TET]ACCAAGA...AACT[BHQ1a-Q] 
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PGC1a SP GATGTGAACGACTTGGAT 
  ASP TTGAAGGCTCATTGTTGTA 
      
POLRMT SP AAGATACTGGAGAAGGATAAGC 
  ASP GCTCTGGAATGGCATCTG 
      
Isl1 SP GTTGGAGAAAGTGGGAAAT 
  ASP CTACCATATCACCTTGTCATT 
      
VACht SP ACTCCTCAACCTTGACTTC 
  ASP CCATTGGACAAGAGAGAAAG 
      
HB9 SP GTGAGAAGAACCGACCCACC 
  ASP CTCCAGAGGCGGTTTCAAGT 
 
Reference genes 
TOPO1 SP TGAGCCAGATAACAAGAA 
  ASP TTGATGCCTTCAGGATAG 
      
14-3-3-Z SP GTAGACCATTTGTCATCCAT 
  ASP AGAAGTAACATAAACCTGTCATA 
      
CYC1 SP ACTGCGGGAAGGTCTCTA 
  ASP TGCCATCGTCAAACTCTAAG 
      
B2M SP TATCCAACATCAACATCT 
  ASP TTCCAATAATCCTGTCAA 
      
UBC SP ATTTTAGGACGGGACTTG 
  ASP CGAGAAGGGACTACTTTT 
      
GAPDH SP GTCGGAGTCAACGGATTT 
  ASP CAACAATATCCACTTTACCAGAG 
 
Pluripotency genes 
KLF4 SP CCTTGCTGATTGTCTATT 
  ASP AAGTCAACGAAGAGAAGA 
      
CMYC SP CGCATCCACGAAACTTTG 
  ASP CTTGCTCGGGTGTTGTAA 
      
LIN28 SP CCAGAGTGAAATGATTAAGTA 
  ASP GAGGATACAAGATGTGAAAA 
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OCT4 SP AGGAAGCTGACAACAATG 
  ASP TGGTTCGCTTTCTCTTTC 
      
SOX2 SP ATGGTTGTCTATTAACTTGT 
  ASP TCTCTCCTCTTCTTTCTC 
 
Neuronal genes 
NEFL SP CTCCCGAAATCAGGTCAA 
  PROBE [5-FAM]CCATCACCAACCAACCAACCAG[BHQ1a-Q] 
  ASP GAGGAAATTCATAGCACAACA 
      
MAP2 SP CAGGAGACAGAGATGAGAA 
  PROBE [5TET]ACAGTTCTATCTCTTCTTCAG[BHQ1a-Q] 
  ASP GGAGTGATGGCAGTAGAC 
      
TUBB3 SP CATCCAGGAGCTGTTCAA 
  PROBE 
[AminoC6+TxRed]CGCATCTCCGAGCAGTTCAC[BHQ2a-
Q] 
  ASP GTCGTTCATGTTGCTCTC 
      
NSE SP TGAGGGATGGAGACAAAC 
  ASP GAGACCTGAGCTGATGAG 
 
Glial genes 
GFAP SP CCGTCTGGATCTGGAGAG 
  ASP TCCTCCTCGTGGATCTTC 
      
GLT-1 SP GACAGTCATCTTGGCTCAG 
  ASP GAGCAGCAGATTCTTCCC 
 
Figure 3. Primer sets used in the present study including sense (SP) and 
antisense primers (ASP). For multiplex assays, probe sequences are given. 
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2.6 mtDNA copy number 
MtDNA copy number was determined using a four-color multiplex qPCR assay 
targeting human mtDNA-encoded genes around the mitochondrial genome (12s rRNA, 
ND2, CO3, ND4). Absolute quantification of DNA samples was based on human mtDNA 
copy number standards run on the same plate. The mtDNA standards were prepared as 
described previously [129]. Briefly, human genomic DNA was purchased from Roche 
and treated with limiting amounts of Plasmid-Safe ATP-dependent DNase (Epicentre 
Biotechnologies, Madison, WI) according to manufacturer recommendations. This 
procedure selectively digests all forms of DNA but does not affect closed circular or 
nicked circular double-stranded DNA, leaving only circular mtDNA. MtDNA was further 
purified according to protocols for the UltraClean GelSpin DNA purification kit (MO BIO 
Laboratories, Calsbard, CA) and quantified with a DNA Quant-iT assay kit (Invitrogen, 
Calsbard, CA) and the linear band was visualized on a 0.8% agarose gel. 
 
2.7 Confocal microscopy and immunofluorescence  
For immunocytochemistry analysis cells were seeded in 35 mm glass bottom 
confocal dishes. On D21 cells were fixed in 4% paraformaldehyde and 4% sucrose in 
PBS at room temperature for 15 minutes. Cells were incubated for 60 minutes in 
blocking buffer (5% goat serum, 1% BSA, 0.1% Triton-X in PBS). Cells were incubated 
overnight at 4°C with primary antibody (1:100) diluted in 5% goat serum. Primary 
antibodies included rabbit anti-ChAT (Millipore), mouse anti-nestin (abcam), mouse anti-
TOMM20 (abcam), mouse anti-Isl1/2 and HB9 (MNR2; DHSB), and rabbit anti-MAP2 
(Millipore). Alexa Fluor conjugated secondary antibodies (1:400, Life Technologies) 
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were added for 60 minutes at room temperature. After washes, VECTASHIELD 
mounting media with DAPI was added for visualization of nuclei. Images were obtained 
with an Olympus FV1000 confocal microscope. For TOM20 and percent positive 
quantitation, ten representative fields were taken and analyzed using MetaMorph image 
analysis software (Molecular Devices). For TOMO20 staining pixel values were 
normalized to number of cells in each image, identified by DAPI nuclear staining. 
 
2.8 Western blot analysis 
Cell homogenates were prepared by dissociating cells with TrypLE™ and 
washing three times with PBS. After the last wash samples were resuspended in RIPA 
buffer (50 mM Tris-HCl, 1% NP-40, 0.25% Na deoxycholate, 150 mM NaCl, 1 mM 
EGTA, 1 mM Na orthovanadate, 1 mM Na fluoride, pH 7.4) with 10 ul/ml Protease 
Inhibitor Cocktail Set I (Calbiochem) and 10 ul/ml of 100 mM PMSF (Sigma), followed 
by water bath sonication for 2 minutes. Samples were incubated on ice for 30 minutes 
and vortexed every 5 minutes prior to centrifugation at 15,000 x g for 10 minutes at 4°C 
to remove cellular debris. The supernatant was transferred to a new microcentrifuge 
tube and stored at -20°C for later analysis.  
Equal concentration (20-25 ug) of total cell protein from each sample was 
separated on a 4-12% Bis-Tris Criterion precast gel at 200 V for 1 hour using sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were 
transferred to nitrocellulose membranes using the iBlot transfer system (Invitrogen). 
After blocking the membrane for 1 hour with Odyssey® blocking buffer (LI-COR 
Biosciences) the membrane was probed primary antibody overnight at 4°C. Primary 
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antibodies were diluted in blocking buffer with 0.1% Tween 20 and included the 
MitoProfile® Total OXPHOS Human WB Antibody Cocktail (1:200, ab110411, Abcam), 
mouse anti-VDAC1 (1:1000, Abcam), and rabbit anti-beta actin (β-actin; 1:500, Abcam). 
The membrane was probed with 800CW goat anti-mouse or 680 goat anti-rabbit 
secondary antibodies (1:15000, LI-COR) at RT for 1 hour and band intensity was 
quantified using the Odyssey infrared imaging system (LI-COR, Lincoln, NE).  
 
2.9  XF24 extracellular flux analyzer 
Cell metabolic rates were measured using an XF24 Extracellular Flux Analyzer 
(Seahorse Bioscience) in unbuffered DMEM, pH 7.4 as described previously by our 
group [130]. Briefly, on day 16 cells were seeded onto an XF24 Cell Culture Microplate 
(Seahorse Bioscience) at 60,000 cells/well with 10 µM Y-27632 dihydrochloride, a 
selective inhibitor of Rho-associated protein kinase (ROCK; Tocris) and incubated at 
37°C in 5% oxygen. After 3 days hNSCs were seeded onto the same XF24 Cell Culture 
Microplate at 40,000 cells/well with 10 µM ROCK inhibitor and incubated at 37°C 5% 
oxygen for 24 hours. iPSC-derived cells (D0 and D21) were plated at 60,000 cells/well 
the day before recording. Each cell type was tested at three to four concentrations to 
determine the most reliable plating density. Inhibitors included oligomycin (1 µM) and 
FCCP (0.5-1 µM). OCR and ECAR were normalized to protein concentration (Micro 
BCA Kit, Pierce) for all experiments to account for differences in cell size.  
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2.10 Lentiviral generation and infection 
For generation of the HB9::GFP lentivirus services and products generated by 
the VCU Massey Cancer Center Biological Macromolecule Shared Resource, 
supported, in part, with funding from NIH-NCI Cancer Center Support Grant P30 
CA016059 were used. Addgene plasmid 37080 [124] was cotransfected with packaging 
and envelope plasmids cCMVR8.74 and MD2G. Transfection and viral concentration 
were performed using standard published protocols. Virus titer was 5 x 10^7 TU/mL in 
PBS. Cells were infected at a multiplicity of infection (MOI) of 3-5 with 8 ug/ml protamine 
sulfate 5 days before recording. 
 
2.11 Electrophysiology  
For whole-cell patch-clamp experiments cells were differentiated for 28 days. 
Two days before recording cells were moved to 12 mm diameter circular glass 
coverslips (neuvitro). On the day of recording coverslips were placed in a recording 
chamber on the stage of an inverted microscope (Olympus). An Axopatch 200B 
amplifier (Molecular Devices) and pClamp 10 software (Axon Instruments) were used to 
record whole-cell currents. Patch pipettes were pulled from thick-walled borosilicate 
glass capillaries to resistances of 2-4 mΩ and filled with internal solution containing 120 
mM KCl, 2 mM MgCl2, 1 mM CaCl2, 10 mM EGTA, 10 mM HEPES, 2 mM Na2ATP (pH 
7.2). Extracellular solution consisted of 135 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1 mM 
CaCl2, 10 mM HEPES, and 10 mM glucose (pH 7.4). Action potential threshold was 
determined as the voltage at which the d(V)/d(T) function deviated from zero. Action 
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potential height was determined by measuring the threshold to the peak of the action 
potential.  
 
2.12 Statistical analysis 
All results are expressed as the mean ± standard error of the mean (SEM). The 
number of experiments performed is denoted by n.  Outliers were excluded at the 
p<0.05 level by Grubbs’ test. Statistics were calculated using one-way ANOVA or 
unpaired t-test in Prism software (GraphPad, Prism). P-values <0.05 were considered 
statistically significant.  
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CHAPTER THREE 
Generation of motor neurons from embryonic and iPSC-derived human neural 
stem cells 
3.1 Rationale and Hypothesis 
 The present study tested the ability of factors crucial for the patterning of motor 
neurons in the developing spinal cord to differentiate human neural stem cells (hNSCs) 
into motor neurons in culture. This will allow for the study of a cell type currently only 
accessible in post mortem tissue or in animal models. Additionally, reprogramming cells 
from patients may prove beneficial in the modeling of complex diseases with no single 
genetic cause, including ALS. Since iPSCs have the same genetic profile as living 
patients they may replicate disease pathology. There is evidence that disease 
processes begin decades before symptom onset, so these ‘young’ cells may give us 
insights into disease mechanisms. 
Previous studies have differentiated hESCs and iPSCs derived from fibroblasts 
into motor neurons [91-97, 128, 131-134]. As summarized in Figure 4, this study uses 
human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) from 
healthy individuals and lays the groundwork for replicating these studies using patient 
cells. Peripheral blood mononuclear cells (PBMCs) were used for reprogramming 
instead of fibroblasts (Figure 4). iPSCs derived from PBMCs display an epigenetic 
profile closer to hESCs than iPSCs derived from fibroblasts [89] and PBMCs are 
exposed to fewer environmental mutagens. Previous studies have shown that PBMCs 
can be reprogrammed into iPSCs but it remains to be shown if they can differentiate into 
motor neurons.  
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Figure 4. Schematic of motor neuron differentiation. Neural stem cells from hESC 
and iPSC-derived cells will be differentiated into motor neurons  
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3.2 Statement of contributions 
 This chapter contains data collected by three individuals. Amy Ladd generated 
that data represented in Figure 5 showing mtDNA encoded gene expression in ALS and 
control PBMCs. This figure was reproduced from a recent publication from our lab [26]. 
For iPSC generation Amy Ladd and I isolated PBMCs from peripheral blood and Paula 
Keeney performed all of the cell culture work to generate the iPSC cell line (Figure 6 
and 7B). I performed all cell culture and experiments with the H9 hESC-derived cell line 
and the iPSC cell line after neural induction (Figures 7A, 9, and 10) 
 
3.3 Results 
3.3.1 Generation of iPSCs from PBMCs. 
Peripheral blood samples from nine sporadic ALS (sALS) patients and 11 controls 
were collected according to an IRB approved protocol. If possible, spouses were used 
as controls. This allowed for a convenient, relatively age-matched, gender balanced 
control group. Additionally, these individuals likely lived together and would therefore be 
exposed to a similar environment. Although ALS iPSCs are not used in this study, 
isolated PBMCs are frozen for future reprogramming use from all patients.  
Following isolation, PBMCs were cultured for two weeks in conditions favoring 
erythroblast expansion and eliminating lymphocytes. This is an important step, as 
lymphocytes (70-90% of PBMCs) commonly rearrange their DNA and thus stem cell 
lines derived from them may have an increased rate of forming lymphomas [135]. 
Additionally, this culture protocol enriches for CD34+ hematopoietic stem cells without 
the need for cell sorting. Interestingly, PBMCs from ALS patients have decreased 
  
39 
mitochondrial DNA encoded gene expression compared to controls [26]. This mirrors 
what is seen in post mortem spinal cord from sALS patients[26]  and may suggest a 
systemic bioenergetic impairment in these individuals. These findings, along with 
decreased growth rates and survival of the sALS iPSC cell lines support the hypothesis 
that ALS cells may be more sensitive to stress, as seen in familial ALS (fALS) derived 
cells [93]. 
As described in Figure 4, after expansion, PBMCs were reprogrammed into iPSCs 
by electroporation of five reprogramming factors, Oct4, Sox2, Klf4, c-Myc, and Lin28 as 
well as a plasmid containing the SV40 large T antigen. As shown in Figure 5A, two 
weeks after reprogramming live cells express TRA-1-60, a human stem cell antigen and 
early marker of pluripotency. As iSPC colonies formed, starting at day 21, they were 
identified and expanded. To confirm pluripotency of the iPSC cell line, three colonies 
were chosen for qPCR analysis. Figure 5B shows increased expression of genes 
encoded by the reprogramming plasmid including Oct4, Sox2, and Lin28 in iPSC 
colonies compared to PBMCs (Figure 5B; *p<0.05, **p<0.01).   
After 10 days in neural induction media, NSC colonies were picked and expanded. 
qPCR revealed decreased expression of the plasmid encoded genes Oct4, Sox2, and 
Lin28 in NSCs (Figure 5B; *p<0.05, **p<0.01). This suggests that the plasmid is no 
longer being expressed.  
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Figure 5. Generation of iPSCs from blood A) Expression of TRA-1-60, an early 
marker of pluripotency, after reprogramming B) Expression of genes encoded by the 
reprogramming plasmid in peripheral blood mononuclear cells (PBMCs), induced 
pluripotent stem cells (iPSCs), and neural stem cells (NSCs) (*p<0.05, **p<0.01). SOX2 
expression was undetectable in PBMCs 
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3.3.2 Neural induction of iPSCs 
In order to confirm successful neural induction of iPSCs, cells were stained with the 
human neural stem cell (hNSC) marker, nestin. Nestin is an intermediate filament 
protein expressed in neuroepithelial precursors that become neurons and glia [136]. A 
representative confocal image is shown in Figure 6A. 67% of cells stained positive for 
nestin. To test if iPSC-derived hNSCs display an early commitment to a particular 
lineage, expression of a panel of neuronal and glial genes were assessed by qPCR. 
Neuronal markers neural filament light chain (NEFL), microtubule-associated protein 2 
(MAP2), and beta III tubulin (TUBB3) increased expression during neural induction 
(Figure 6B; *p<0.05). 
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Figure 6. Neural induction of iPSCs. A) A representative confocal image showing 
expression the neural stem cell marker nestin (green) and DAPI nuclear staining (blue) 
after neural induction B) qPCR analysis of neuronal markers in iPSCs and after neural 
induction (*p<0.05) 
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3.3.3 Spontaneous differentiation of NSCs into neurons, astrocytes and 
oligodendrocytes 
While the iPSC cell line was being established, experiments were performed using 
commercially available hNSCs. The hNSC line used is derived from NIH approved H9 
(WA09) hESC cells. These cells have a normal human female karyotype and can 
remain in an undifferentiated state in the presence of growth factors or can differentiate 
into neurons, astrocytes or oligodendrocytes. Starting from hNSCs instead of hESCs 
allowed for an accelerated differentiation protocol since neural induction had already 
been completed. In addition, these cells are easier to culture since they are adherent, 
compared to hESC and iPSCs, which are often cultured and differentiated as floating 
embroyid bodies. Over 90% of these cells stained positive for the neural stem cell 
marker nestin on day 0 (D0; Figure 7). Many D0 cells also stained positive for the 
neuronal marker MAP2 but did not stain positive for the glial markers GalC or GFAP 
(Figure 7). 
In order to test the differentiation capacity of hNSCs, growth factors bFGF and EGF 
were withdrawn from cell culture media for 14 days. This resulted in loss of nestin 
staining and spontaneous differentiation of cells into neurons (MAP2+), 
oligodendrocytes (galactocerebroside, GalC+), and astrocytes (GFAP+; Figure 7).  
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Figure 7. Neuronal and glial markers after spontaneous differentiation. Expression 
of the neural stem cell marker nestin, the neuronal marker MAP2, and the glial markers 
GALC and GFAP at day 0 (D0) and day 14 (D14) after spontaneous differentiation in 
hESC-derived cells 
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3.3.4 Motor neuron differentiation of hESC-derived cells 
 To test the ability of commercially available hNSCs to differentiate into 
specialized cell types we induced motor neuron differentiation with retinoic acid (RA) 
and purmorphamine (PM), a sonic hedgehog (SHH) agonist. SHH has been shown to 
regulate ventralization of neural tissues [35]. As shown in Figure 8A, qPCR analysis 
revealed that after 21 days of differentiation (D21) cells significantly increased 
expression of post mitotic motor neuron genes ISL1 and HB9 (t-test D0 vs D21, 
*p<0.05, **p<0.01). Phase contrast images on D21 revealed morphological changes 
including an extensive network of processes (Figure 8B). On D21 46% of cells stained 
positive for both MAP2 and HB9 and 51% stained positive for MAP2 and ISL1/2 (Figure 
8C). GFAP staining was not observed in these cultures. Collectively, these findings 
suggest that cells acquire a motor neuron molecular phenotype by D21. Analysis 
comparing different passage numbers revealed that higher passage numbers resulted 
in more variable gene expression data, therefore all data were generated from cells with 
passage numbers less than 33. 
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Figure 8. Motor neuron differentiation of hESC-derived hNSCs. A) qPCR 
expression of spinal motor neuron markers HB9 and ISL1 on day 0-28 (D0-D28) of 
motor neuron differentiation (*p<0.05, **p<0.01) B) Representative phase contrast 
images of D0 and D21 cells C) Immunostaining of MAP2 (red), HB9 or ISL1 (green), 
and DAPI (blue) on D0 and D21 
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3.3.5 Differentiation of motor neurons from iPSC-derived cells 
 For motor neuron differentiation of iPSC-derived cells the protocol was modified 
based on a recent publication [128]. The differentiation schematic is shown in Figure 
9A. RA and PM concentrations remained the same, but small molecules SB435142 
(SB) and LDN193189 (LDN) were used to induce neuralization by inhibition of SMAD 
signaling. Smoothened agonist (SAG) was added in addition to PM to further increase 
sonic hedgehog signaling. For increased neurotrophic support, GDNF and CNTF were 
added after day 14. Preliminary data revealed wide variations in gene expression in 
cells of different passage number; therefore all cells were cultured for a minimum 
amount of time, 4-6 days after thawing, before motor neuron differentiation was started. 
Figure 9B shows representative phase contrast images of D0 and D21 cells and is very 
similar to what was seen in hESC-derived cells. Expression of motor neuron markers 
HB9 and ISL1 were undetectable in D0 cells by qPCR and increased significantly on 
D21 (Figure 9C; **p<0.01, ***p<0.001). The expression of vesicular acetylcholine 
transporter (VACHT) was also significantly increased on D21 compared to D0, 
suggesting that these cells are cholinergic neurons (Figure 9C). To further confirm 
motor neuron identity, cells were stained with HB9, ISL1/2, and MAP2. Figure 9D 
shows staining for these markers on D21 but not on D0. 
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Figure 9. Motor neuron differentiation of iPSC-derived hNSCs. A) Schematic of the 
motor neuron differentiation protocol showing timing of neuralization with SB and LDN, 
caudalization with RA, induction of sonic hedgehog signaling with SAG and PM, as well 
as neurotrophic support from day 14 on with CNTF and GDNF B) Representative phase 
contrast images of D0 and D21 cells C) Expression of motor neuron genes HB9, ISL1, 
and VACHT (**p<0.01, ***p<0.001) D) Immunostaining of MAP2 (red), HB9 or ISL1 
(green), and DAPI (blue) on D0 and D21 
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3.4 Summary 
 In summary, these studies demonstrate the ability to generate iPSC cell lines 
from PBMCs without viral expression or DNA integration of plasmid. The finding of 
decreased mtDNA encoded gene expression in sALS PBMCs suggests that these cells 
may replicate disease pathology since this mirrors what is seen in post mortem spinal 
cord from sALS patients. Secondly, commercially available hNSCs were differentiated 
into multiple neuronal cell types, including motor neurons. This accelerated protocol, 
without the need for suspension culture, may prove to be advantageous in labs without 
access to or experience with culturing stem cells. Finally, iPSCs were successfully 
induced to become motor neurons, based on multiple gene and protein markers. These 
cells may be used to understand human motor neuron physiology. Collectively, these 
studies set the stage for the study of human motor neurons and reprogramming and 
differentiation of ALS patient cells in the future. 
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CHAPTER FOUR 
Mitochondrial biogenesis increases as cells differentiate from neural stem cells 
into motor neurons 
 
4.1 Rationale and Hypothesis 
 Previous studies have demonstrated that both hESCs and iPSCs produce ATP 
mainly through glycolysis and that during differentiation there is a switch to energy 
production by oxidative phosphorylation (OXPHOS). The mechanism underlying this 
switch remains unknown, but an increase in mitochondrial mass, mtDNA copy number 
and ATP production has been seen during spontaneous differentiation of hESCs into all 
three germ layers [108, 109]. Based on these findings, this series of experiments 
hypothesized that mitochondrial biogenesis would increase during motor neuron 
differentiation. Mitochondrial biogenesis is the process by which cells increase their 
mitochondrial components and includes upstream mRNA signaling, mtDNA copy 
number and gene expression, electron transport chain protein expression, and 
mitochondrial mass. Although many of these processes are regulated by the same 
mechanisms, they may also act independently of each other, resulting in an increase of 
one without an increase in all of them. Figure 10 depicts how mitochondrial biogenesis 
‘master regulator’ PGC1-α increases transcription of genes encoding mitochondrial 
proteins as well as mitochondrial and non-mitochondrial sources of cellular ATP 
production.  
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Figure 10. Mitochondrial biogenesis and ATP production. A) Anaerobic glycolysis is 
the process by which glucose is converted to pyruvate. Pyruvate can be converted into 
lactate anaerobically or oxidatively decarboxylated by the TCA cycle to electrons (e-) 
that reduce NAD+/FAD+ to NADH/FADH which are then oxidized by the electron 
transport chain (ETC) to generate ATP during oxidative phosphorylation (OXPHOS) B) 
Mitochondrial biogenesis regulator PGC-1α binds to NRF1/2 and ERRα, initiating gene 
expression of mitochondrial components. 
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4.2 Results 
4.2.1 Mitobiogenesis signaling increases with motor neuron differentiation 
 In order to assess mitochondrial biogenesis as cells differentiate from hESC-
derived hNSCs to motor neurons, qPCR targeting biogenesis genes was performed at 
seven-day time points. Figures 11A and B shows increased levels of PGC-1α at D21, 
POLG at D28, and ERRα, NRF1 and POLRMT at D21 and D28 compared to D0 (n=4-6, 
p<0.01, one-way ANOVA, *p<0.05, **p<0.01, ***p<0.001, Dunnett’s multiple 
comparisons test). NRF2, TFAM, and TFMB2 expression remained unchanged (p<0.05, 
one-way ANOVA). Based on these findings D21 was chosen as the time point for 
analysis of iPSC-derived cells. There was no change in PGC-1α, POLG, POLRMT, or 
TFAM expression but there was an increase in ERRα at D21 in iPSC-derived cells 
(Figure 11C; n=3, *p<0.05, unpaired t-test).  
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Figure 11. Mitochondrial biogenesis signaling during motor neuron 
differentiation. Expression of upstream (A) and downstream (B) mitochondrial 
biogenesis genes in hESC-derived cells at D0 (hNSCs) and on day 7-28 of motor 
neuron differentiation C) Expression of mitochondrial biogenesis genes in iPSC-derived 
cells at D0 (hNSCs) and D21 (motor neurons). *p<0.05, **p<0.01, ***p<0.001 
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4.2.2 Mitochondrial encoded genes increase with motor neuron differentiation. 
 The nuclear genome encodes most of the proteins that mitochondria require; 
however, mitochondria have their own genome that encodes 13 proteins essential for 
respiratory chain function. To determine if mitochondrial gene expression was increased 
during motor neuron differentiation we measured with qPCR expression of four mtDNA-
encoded genes. Figure 12A shows an increase in ND2 and ND4 expression on D21 
and D28 compared to D0 in hESC-derived cells (n=4-6, *p<0.05, one way ANOVA, 
*p<0.05, Dunnett’s multiple comparisons test). However, there was no statistically 
significant increase in iPSC-derived cells on D21 compared to D0 because of variability 
in the D21 samples (Figure 12B, n=3, p>0.05, unpaired t-test). 
qPCR was also performed with genomic DNA as the input. When analyzed using 
a standard curve of human mtDNA samples we were able to determine the mtDNA copy 
number. This analysis revealed a non-significant decrease in mtDNA copy number in 
hESC-derived cells (Figure 12C), as well as a significant decrease in mtDNA copy 
number in iPSC-derived cells with motor neuron differentiation (Figure 12D; *p<0.05). 
Because the four genes chosen are spatially distributed around the mitochondrial 
genome we are also able to detect mtDNA deletions using this method. Since there are 
no differences in the expression levels of the four genes at any time point we know that 
there are likely no major mtDNA deletions in those areas. 
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Figure 12. Mitochondrial encoded gene expression and mtDNA copy number. A) 
Expression of mitochondrial encoded genes in hESC-derived cells at D0 (hNSCs) and 
on day 7-28 of motor neuron differentiation B) Expression of mitochondrial encoded 
genes in iPSC-derived cells at D0 (hNSCs) and D21 (motor neurons) C) mtDNA copy 
number in hESC-derived cells, and D) iPSC-derived cells. *p<0.05 
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4.2.3 Glycolysis decreases as cells differentiate into motor neurons 
 For respiration analysis oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) were measured simultaneously in adherent cultures using the 
XF24 Extracellular Flux Analyzer. This instrument allows measurement from 20 wells of 
cells plus 4 control wells. ECAR is measured in milli-pH units (mpH) and measures the 
change in pH resulting from the release of protons from the cell during glycolysis. In 
order for these readings to be accurate they must be within the linear range of the XF24 
instrument. In order to determine optimal cell density three or four densities, ranging 
from 20,000 to 80,000 cells per well, were measured for each cell type. The iPSC cell 
line is denoted C42 here. Figure 13 shows basal OCR and ECAR as a function of cell 
number. As seen with both hNSC lines (H9 D0 and C42 D0), 80,000 cells per well gives 
signals beyond the linear range of the XF24 instrument (Figure 13A and C). Based on 
these data as well as variability between wells (data not shown), we chose 40,000 cells 
per well for H9 D0 and 60,000 cells per well for H9 D21, C42 D0, and C42 D21. 
 In order to assess electron transport chain function, a number of inhibitors are 
commonly used including oligomycin, FCCP, rotenone, and antimycin A. Oligomycin is 
added to inhibit ATP synthase, followed by the protonophore FCCP to dissipate the 
proton gradient and measure maximal OCR in an uncoupled state, rotenone to inhibit 
complex I and antimycin A to inhibit complex III. Starting concentrations of these 
inhibitors were chosen based on published protocols [130, 137]. Interestingly, the 
starting concentration of 0.3 µM FCCP was insufficient to uncouple respiration in both 
hESC- and iPSC-derived cells. Since an excess of FCCP can uncouple the plasma 
membrane, it was important to determine the lowest concentration required to uncouple 
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mitochondrial respiration. 0.5-2 µM FCCP were tested in both cell types optimal 
concentration was chosen based on an increase from oligomycin inhibited levels (0.5 
µM for hESC-derived and 1 µM for iPSC-derived). Interestingly, no concentration of 
FCCP increased OCR above basal levels in either cell type. This suggests that cells are 
respiring at maximum capacity. 
Figure 14A shows a representative recording of iPSC-derived cells on D0 
(green) and D21 (blue). Temperature control wells are shown in teal. Dotted lines 
represent an average of the three time points. Respiration analysis was performed on 
hESC- (Figure 14B) and iPSC-derived cells (Figure 14C). There was no change in 
basal respiration or after addition of any of the inhibitors on D21 compared to D0 in 
either cell type (p>0.05, unpaired t-test). We did not detect changes in oxygen 
consumption coupled to ATP synthesis or max respiratory capacity in either cell type.  
ECAR was measured simultaneously in these cultures. There was a significant 
decrease in ECAR at D21 compared to D0 in both hESC-derived cultures (Figure 15A), 
as well as iPSC-derived cultures (Figure 15B; *p<0.05). This suggests a decreased 
usage of glycolysis in motor neurons compared to hNSCs.  
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Figure 13. OCR and ECAR values as a function of cell density A) hESC-derived 
cells (H9) on D0 and B) D21 C) iPSC-derived cells (C42) on D0 and D) D21 
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Figure 14. Bioenergetic profile of hNSCs and motor neurons. A) Representative 
measurements from iPSC-derived cells showing oxygen consumption rate (OCR) after 
the addition of various electron transport chain inhibitors. (1) represents OCR coupled to 
ATP synthesis, (2) is the amount of proton leak across the mitochondrial inner 
membrane, and (3) is max respiratory capacity B) OCR normalized to cell protein in 
hESC-derived cells C) iPSC-derived cells 
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Figure 15. ECAR in hNSCs and motor neurons. Extracellular acidification rate 
(ECAR), a measure of glycolysis, normalized to cell protein in hESC-derived cells (A), 
and iPSC-derived cells (B). *p<0.05 
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4.2.4 Electron transport chain proteins, but not mitochondrial mass, increase with 
differentiation 
 To further investigate mitochondrial biogenesis as hNSCs differentiate into motor 
neurons we measured protein expression of electron transport chain proteins. As shown 
in Figure 16B, in hESC-derived cells, levels of complex II (CII) and complex V (CV) 
proteins were significantly increased on D21 and D28, respectively (n=3-4). All other 
proteins were increased at both time points but did not reach statistical significance. To 
increase statistical power, respiratory proteins normalized to their representative D0 
were combined and this revealed a significant increase on D21 and D28 (Figure 16C). 
In iPSC-derived cells there was a significant increase in complex III (CIII) and complex 
V (CV) on D21 (n=4, Figure 16E). When combined, respiratory proteins were 
significantly increased on D21 (Figure 16F).  
 To measure mitochondrial mass protein expression of an outer mitochondrial 
membrane protein, voltage-dependent anion channel 1 (VDAC1), was analyzed. 
Interestingly, the VDAC1 protein levels were unchanged in hESC-derived cells on D21 
and D28 (Figure 17A) and iPSC-derived cells on D21 compared to D0 (Figure 17B). 
To further confirm that mitochondrial mass is unchanged during motor neuron 
differentiation, hESC-derived cells were immunostained for the translocase of outer 
mitochondrial membrane, TOM20. Localization of mitochondria changed from 
perinuclear in hNSCs to extended into long processes on D21. However, when TOM20 
fluorescence in 10 representative fields was normalized to cell number there was no 
difference in fluorescence between D0 and D21 (Figure 17D). 
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Figure 16. Respiratory chain protein expression in hNSCs and motor neurons. A) 
Representative western blot of hESC-derived cells B) Western blot quantitation 
normalized to beta actin C) Respiratory chain protein expression in hESC-derived cells 
D) Representative western blot of iPSC-derived cells E) Quantitation normalized to beta 
actin F) Respiratory chain protein expression in iPSC-derived cells. *p<0.05, **p<0.01, 
***p<0.001 
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Figure 17. Mitochondrial mass in hNSCs and motor neurons. A) VDAC1 protein 
expression in hESC-derived cells normalized to beta actin B) VDAC1 protein expression 
in iPSC-derived cells normalized to beta actin C) Representative image of TOM20 
staining in hESC-derived cells E) Quantitation of TOM20 staining in hESC-derived cells 
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4.3 Summary 
 In summary, this series of experiments demonstrated that mitochondrial 
biogenesis signaling and electron transport chain protein expression increases during 
motor neuron differentiation of hNSCs. This is not accompanied by an increase in 
mtDNA copy number or mitochondrial mass, suggesting that the total amount of 
mitochondria in the cell is not changing. Although there is no change in respiration rates 
there is a significant decrease in glycolysis between hNSCs and motor neurons. 
Together, these results indicate that mitochondrial biogenesis is increased during motor 
neuron differentiation and is accompanied by a reduction in glycolysis. 
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CHAPTER FIVE 
Electrophysiological changes as cells differentiate into motor neurons 
 
5.1 Rationale and Hypothesis  
 Development of voltage-activated currents and the generation of action potentials 
are crucial to motor neuron maturation in vivo. In order to explore these properties in 
vitro we performed whole cell patch clamp on hESC- and iPSC-derived motor neurons. 
We expected that after four weeks of motor neuron differentiation cells would display 
currents characteristic of excitable cells and generate action potentials following 
depolarizing current injection. These findings will set the stage for further analysis of 
voltage gated ion channels underlying motor neuron excitability in healthy and disease 
states. 
 
5.2 Results 
5.2.1 Identifying motor neurons in live culture 
 In order to identify motor neurons in live cultures a lentivirus was generated with 
GFP under control of a motor neuron specific transcription factor (HB9). To increase the 
rate of viral infection, cells were treated with the cationic polymer protamine sulfate. This 
polymer was chosen over polybrene, a commonly used viral infection enhancer, 
because this latter agent was toxic to motor neurons used in this study. Optimal 
multiplicity of infection (MOI) and virus incubation time was determined for each cell 
type. Cells were infected with the lentivirus 5 days before recording and replated on 
glass coverslips 2 days before recording. 
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5.2.2 Passive membrane properties of hESC and iPSC-derived cells  
 Passive membrane properties were recorded after the whole cell patch clamp 
configuration was acquired and monitored over the course of the recording on day 28 of 
motor neuron differentiation. Membrane capacitance (Cm) was 14.88 ± 1.42 pF for 
hESC-derived cells (n=5) and 9.75 ± 0.45 pF for iPSC-derived cells (n=7; Figure 18A). 
Resting membrane potential (Vm) was -39 ± 3.84 mV (n=6) in hESC- and -31.6 ± 4.82 
mV (n=10) in iPSC-derived cells (Figure 18B). Membrane resistance (Rm) was 2±0.3 
GΩ in hESC-derived cells (n=5) and 3.77±0.85 GΩ in iPSC-derived cells (n=6; Figure 
18C). None of these parameters were statistically different between cell types. 
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Figure 18. Passive membrane properties in hNSC-derived motor neurons. A) 
Membrane capacitance (Cm), B) Resting membrane potential (Vm), and C) Membrane 
resistance (Rm) in hESC- and iPSC-derived motor neurons. 
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5.2.3 Voltage gated currents characteristic of excitable cells 
 A series of voltage steps from a holding potential for -60 revealed inward and 
outward currents characteristic of sodium and potassium currents, respectively. Figure 
19A (i) shows a representative recording from an iPSC-derived motor neuron on D28. 
The presence of sodium channels was confirmed by the addition of 2 µM tetrodotoxin 
(TTX, Figure 19A (ii)). In order to determine current densities normalized to cell size, 
peak current amplitude was divided by cell capacitance. Mean sodium current density 
was -29.10 ± 8.29 pA/pF (n=5) for hESC-derived cells and -37.51 ± 5.39 pA/pF (n=7) for 
iPSC-derived cells (Figure 19B). Mean potassium current density was 29.55 ± 9.25 
pA/pF (n=5) for hESC-derived cells and 78.91 ± 8.04 pA/pF (n=7) for iPSC-derived cells 
(Figure 19C). Interestingly, iPSC-derived motor neurons had a significantly higher 
potassium channel density than hESC-derived cells.  
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Figure 19. Voltage gated currents in hNSC-derived motor neurons. A) (i) A 
representative voltage clamp trace from an iPSC-derived motor neuron (ii) the same cell 
after the addition of 2 µM (TTX) to block voltage activated sodium channels. B) Mean 
sodium current density and C) Mean potassium current density in hESC- and iPSC-
derived cells ***p<0.001 
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5.2.4 Action potential firing of stem cell derived motor neurons 
 Action potentials were elicited by a series of current pulses of increasing injected 
current amplitude under the current clamp mode of the patch clamp technique. 
Approximately 40% of hESC-derived cells and 60% of iPSC-derived cells fired action 
potentials on D28. A representative trace from a hESC-derived cell is shown in Figure 
20A. After action potential generation was confirmed, the minimum amount of current 
injection necessary to generate an action potential, rheobase, was determined by 
increasing the current injection by 0.01 nA. Rheobase was 23.75 ± 9.44 pA in hESC-
derived motor neurons (n=4) and -10.75 ± 11.88 pA in iPSC-derived motor neurons 
(n=4; p>0.05; Figure 20B). The fact that some iPSC-derived cells fire action potentials 
after hyperpolarizing current injection suggests the ability for spontaneous action 
potential formation. The threshold potential for the upstroke of the action potential and 
action potential height was similar for both cell types (Figure 20B). 
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 Vm (mV) Rheobase    
(pA) 
AP threshold    
(mV) 
AP height 
(mV) 
hESC-
derived 
-39.0 ± 3.84 23.75 ± 9.44 22.66 ± 7.48 -41.73 ± 10.14 
iPSC-
derived 
-31.6 ± 4.82 -10.75 ± 11.88 24.72 ± 4.18 -41.12 ± 5.02 
 
Figure 20. Action potential generation in hNSC-derived motor neurons. A) A 
representative current-clamp recording showing action potential formation in a hESC-
derived motor neuron B) The resting membrane potential (Vm), minimum current 
injection required to fire an action potential (rheobase), action potential (AP) threshold, 
and AP height for both cell types 
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5.3 Summary 
 Taken together, these preliminary results provide evidence that cells develop 
voltage gated channels characteristic of excitable cells and are able to generate action 
potentials on D28 of motor neuron differentiation. Similar effects were seen in hESC- 
and iPSC-derived cells. Combined with mRNA and protein analysis, these findings 
suggest that hNSC-derived cells are developing into functional motor neurons. These 
studies set the stage for future analysis of stem cell derived motor neurons including the 
alteration of excitability by pharmacological means. 
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CHAPTER SIX: DISCUSSION 
 
6.1 Generation of motor neurons from hNSCs 
 The goal for the first set of studies was to generate motor neurons from hNSCs. 
In order to develop a protocol for patient cell use we reprogrammed PBMCs into iPSCs. 
Following neural induction 67% of these cells stained positive for the hNSC marker 
nestin. These cells, as well as commercially available hESC-derived hNSCs (>90% 
nestin positive) were further differentiated into motor neurons. After 21 days of motor 
neuron differentiation cells had significantly increased expression of genes normally 
found in motor neurons including the motor neuron specific transcription factor HB9. 
~45% of hESC- and ~10% of iPSC-derived cells co-stained positive for markers of post-
mitotic spinal motor neurons and a more general neuronal marker. The findings in 
hESC-derived cells were consistent with a previous study using a similar protocol which 
reported ~30% motor neurons, but iPSCs showed a much lower rate of motor neuron 
generation. These results demonstrate for the first time that iPSCs derived from PBMCs 
can differentiate into motor neurons.  
There was a higher percentage of motor neurons in hESC- compared to iPSC-
derived cultures (~45% vs ~10%, respectively). This may be due to more efficient neural 
induction since hESCs were >90% nestin positive compared to 67% in iPSC-derived 
cells. This could be also be due to changes in the protocol including a shortened 
embryoid body stage and only four days of dual SMAD inhibition compared to seven in 
the previous study [128]. 
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Motor neurons derived from hPSCs give us the ability to study a cell type 
previously only accessible in post mortem tissue. However, the artificial environment in 
which they are grown has limitations. We have shown that retinoic acid (RA) and 
purmorphamine (PM) exposure is sufficient to induce motor neuron differentiation in 
hESC-derived cells but there are a number of other signaling molecules present in the 
developing embryo that were not added in vitro. In order to more closely replicate 
physiological conditions for the iPSC-derived motor neuron differentiation protocol, we 
added small molecules to inhibit SMAD signaling and BDNF during early differentiation 
and GDNF/CNTF for trophic support after day 14. Previous studies have shown that 
SMAD inhibition efficiently neutralizes hNSCs [138, 139]. Another artificial aspect of this 
culture environment is that it does not allow motor neurons to interact with other cell 
types including glia. The lack of GFAP staining is consistent with a previous study using 
a similar protocol [128] and suggests that there are no astrocytes, but we did not 
perform oligodendrocyte staining. Furthermore, these motor neurons do not form 
functional synapses with muscle, their in vivo targets. Previous studies have shown the 
ability of hESC- and iPSC-derived motor neurons to make functional synapses on 
muscle cells in culture but we do not yet know how this affects motor neuron maturation 
and firing. Finally, traditional cell culture grows cells in a single layer, compared to the 
three dimensional nature of tissue. There has been recent interest in developing three-
dimensional cell culture systems but much work remains if this is to be a feasible model 
for more than a few select labs (for a review see [140]. A three-dimensional culture 
system would provide the spatial organization of tissue, in addition to allowing more 
accurate gradient signaling important during development. 
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 PBMCs were chosen as starting material for reprogramming over fibroblasts, 
which are more commonly used. Collecting peripheral blood is a much simpler and less 
invasive procedure than a skin punch for fibroblast collection. Since these cells are not 
exposed to environmental mutagens they may be clinically more favorable due to less 
DNA mutations. Furthermore, PBMCs have a DNA methylation profile that more closely 
resembles hESCs [89], suggesting that they may reprogram more easily. Indeed, a 
previous study found that PBMCs could be reprogrammed with greater efficiency and 
two weeks faster than fibroblasts [89]. PBMCs may also more accurately replicate 
disease pathology. The current study showed that PBMCs from sALS patients had less 
mtDNA encoded genes compared to control patients [26]. This replicates what is seen 
in post mortem spinal cord of ALS patients [26]. Blood cells are unaffected in ALS and 
this decrease in mitochondrial gene expression may represent a systemic bioenergetic 
impairment that has not been previously characterized. If motor neurons derived from 
these cells share the same decreased expression they may be a useful model of sALS. 
Furthermore, if mtDNA gene expression is consistently decreased in all ALS patients 
this panel of genes may be used as a biomarker for ALS. 
 
6.2 Mitobiogenesis signaling in hPSC-derived motor neurons 
 The goal for this series of experiments was to investigate mitochondrial 
biogenesis during motor neuron differentiation. Gene expression of mitochondrial 
biogenesis ‘master regulator’ PGC-1α and many of its downstream targets were 
increased in hESC-derived cells during differentiation and expression peaked on day 
21. This is consistent with PGC-1α activating ERRα and NRF1 to increase transcription 
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of downstream POLG and POLRMT. Expression of mitochondrial transcription factors 
TFAM and TFMB2 was unchanged, consistent with no significant change in mtDNA 
copy number in these cells. iPSC-derived cells increased expression of ERRα on day 
21. The finding that not all mitobiogenesis genes were increased could mean that these 
cells increase mitobiogenesis gene expression earlier or later in the differentiation 
process, given that only one time point was analyzed in these cells. Expression of two 
mtDNA-encoded genes, ND2 and ND4, was also increased in hESC-derived cells on 
D21. However, there was too much variation in iPSC-derived samples to determine a 
statistically significant increase. In contrast, mtDNA copy number was decreased 
slightly in hESC- and significantly decreased in iPSC- derived motor neurons.  
Respiration analysis revealed no change in basal respiration between hNSCs 
and motor neurons, but there was a decrease in glycolysis. One limitation of this series 
of studies is that cells were grown and differentiated in 5% oxygen but respiration 
analysis was performed in room air (~20% oxygen). Efforts were made to keep D0 and 
D21 cells in as similar conditions as possible (similar passage number, similar time in 
culture, etc.) but the change in oxygen concentration may have affected the cells. 
Interestingly, neither D0 nor D21 cells increased OCR levels above basal after the 
addition of FCCP. FCCP uncouples the proton gradient across the inner mitochondrial 
membrane, measuring maximum oxygen consumption. The fact that this value never 
exceeds basal levels suggests that the ETC is already running at maximum capacity in 
both cell types. 
Although a decrease in glycolysis may result in increased OXPHOS, it doesn’t 
necessarily mean there is an increase in mitochondrial mass. Mitochondrial mass could 
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remain the same but there could be more ETC complexes or they could be more 
efficient in OXPHOS. Indeed, we found an increase in respiratory proteins but no 
increase in mitochondrial mass. The proteins increased included complex II and V in 
hESC-derived cells and complex III and V in iPSC-derived motor neurons compared to 
hNSCs. One limitation of measuring ETC proteins this way is that each complex is 
composed of many proteins and we only analyzed one for each complex. Additionally, 
we are measuring protein expression; this does not ensure that proteins are assembled 
correctly and that the complex is functioning properly.  
Similarly, an increase in ETC protein expression does not necessarily mean an 
increase in respiration. Respiration is a tightly controlled process. Potential ATP 
production and oxygen consumption capacity could be much greater than what is 
measured at basal levels. The observed increase in ETC protein expression may 
represent potential functioning of the ETC chain. For example, after strenuous exercise 
oxygen consumption and ATP production could be three times what it was at rest 
without any increase in mitochondrial mass. Uncoupling the proton gradient with FCCP 
showed maximal oxygen consumption but says nothing about ATP synthesis. Future 
studies to investigate this may compare ATP generation between hNSCs and motor 
neurons.  
 In summary, this series of studies suggest that some, but not all, mitobiogenesis 
processes increase with motor neuron differentiation of hNSCs. There may be 
differences in the timing of gene expression hESC- vs. iPSC-derived cells but it appears 
that both cell types decrease glycolysis and increase ETC protein expression without a 
change in mitochondrial mass during motor neuron differentiation. One process that the 
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current studies do not address is mitochondrial autophagy (mitophagy). Mitophagy is 
the cellular process that degrades dysfunctional mitochondria. This process could play a 
crucial role in the differentiation process and future studies could explore this.  
 
6.3 Electrical maturation of hPSC-derived motor neurons 
The aim of the last series of studies was to investigate the change in electrical 
properties of cells as they differentiated into motor neurons. Capacitance (Cm) was 
substantially lower in hNSC motor neurons (14.88 ± 1.42 pF in hESC-derived and 9.75 
± 0.45 pF in iPSC-derived) than rat spinal motor neurons at days 15-16 of gestation 
(E15-16; birth is E21-22; Cm = 29.3 ± 1.0 pF) [39]. Similarly, resting membrane potential 
was more depolarized (-39 ± 3.84 mV in hESC-derived and -31.6 ± 4.82 in iPSC-
derived) than in E16 rat motor neurons (-49.3 ± 5.9 mV) [38]. Since Cm increases and 
Vm decreases with motor neuron maturation this may suggest that these cells are still 
very early in development and that later time points may reveal characteristics of more 
mature cells. 
Similarly, sodium channel density was lower than what is seen in embryonic day 4 
(E4) chick spinal motor neurons (-29.10 ± 8.29 pA/pF in hESC0-derived and -37.51 ± 
5.39 pA/pF in iPSC-derived compared to ~70 pA/pF E4). Potassium channel density is 
lower in hESC-derived motor neurons (29.55 ± 9.25 pA/pF) than in embryonic day 4 
(E4) chick spinal motor neurons (~65 pA/pF) but iPSC-derived motor neurons showed 
similar values (78.91 ± 8.04 pA/pF). Previous studies suggest that both current densities 
increase with motor neuron maturation so future studies may wish to investigate these 
properties in cells that were differentiated longer. There was a lot of variability in the 
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mean peak inward and outward currents, consistent with varying rates of maturation. 
Assessing later time points may also result in a greater similarity in maximal currents. 
Action potentials were seen on D28 with threshold and rheobase values similar to a 
previous study [40]. The fact that some iPSC-derived cells fired action potentials in 
response to hyperpolarizing current injection is unusual and may be due to a number of 
factors, including rebound depolarization (Ih) that reached threshold. Future studies are 
planned to confirm this finding as well as to investigate repetitive action potential firing.  
 
6.5 Use of hPSC-derived motor neurons for disease modeling  
 One potential use of patient iPSC-derived motor neurons is their use in modeling 
disease. If these cells replicate disease pathology they may be useful for testing 
promising drug compounds. Both hESC- and iPSC-derived motor neurons from this 
study have been used in preliminary studies to test molecules that mimic the 
neurotrophins, nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). 
Neurotrophins promote neuronal growth and survival, but their structure does not allow 
them to pass the blood brain barrier (BBB) [141]. Dr. Achilleas Gravanis developed 
small molecules, called microneurotrophins, and three analogues were kindly provided 
for our studies. Unlike NGF and BDNF, microneurotrophins can pass the BBB. After 
hESC-derived motor neurons were treated with 100 nM of the three neurotrophin 
analogues, NGF, or vehicle control for four or 24 hours RNA was isolated and sent for 
microarray screening. Gene expression analysis was then performed to identify which of 
the three compounds activated pathways most similar to NGF. The BNN124 analogue 
most closely resembled NGF at both 4 and 24 hours. Based on these promising results, 
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we treated hESC- and iPSC-derived motor neurons with the three analogues, NGF, 
BDNF, or vehicle control for 24 hours and isolated RNA for RNA-sequencing (RNA-
seq). RNA-seq data will be analyzed in the coming months and the findings will be 
published soon after. Both RNA-seq and microarray analyze gene expression; however, 
RNA-seq has a number of advantages. One advantage of RNA-seq is that it can detect 
very low expressing genes because it quantitates absolute rather than relative 
expression. Microarray technology is based on fluorescence and can only detect 
expression over baseline. Another advantage of RNA-seq is that it can detect novel 
isoforms and mutations because it does not require a known sequence like microarray 
does. Microneurotrophins have potential use in many neurodegenerative diseases 
including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, as well 
as in stroke and nerve injury (for a review see [142]).  
  
6.7 Summary and conclusions 
In summary, we have demonstrated the ability to differentiate motor neurons 
from both hESC- and iPSC- derived cells in three weeks. The hypothesis that 
differentiation of human pluripotent stem cells into electrically excitable motor neurons 
will result in increased mitochondrial biogenesis was confirmed at multiple levels.  
Expression of upstream regulatory genes increased, along with increased transcription 
of mtDNA-encoded genes, and increased levels of representative ETC proteins. Despite 
these increases, mitochondrial mass remains unchanged. During this time cells develop 
voltage-gated currents characteristic of excitable cells and are able to fire action 
potentials in response to depolarizing current. 
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6.8 Significance and perspectives 
The findings from this study have implications in multiple areas. Motor neurons 
are lost in a number of other diseases including progressive bulbar palsy, pseudobulbar 
palsy, primary lateral sclerosis, progressive muscular atrophy, and spinal muscular 
atrophy. Being able to generate motor neurons from patient blood cells may aid in the 
development of treatments for these devastating diseases by better understanding 
disease mechanisms and having predictive models to test promising compounds. The 
current study also sets the stage for looking at mitobiogenesis in other cell types lost in 
neurodegenerative disease including Parkinson’s and Alzheimer’s disease. Since 
mitochondrial dysfunction is a common theme in many neurodegenerative diseases a 
better understanding of how this pathway is regulated may lead to more effective drug 
targets. The findings in the present study suggest that PGC-1α acts through a NRF1-
ERRα mediated pathway to increase mitobiogenesis in hESC-derived cells and this may 
represent a target to increase mitobiogenesis. Together, findings from this study provide 
the first evidence that iPSCs from blood can differentiate into electrically active motor 
neurons and that mitobiogenesis is increased during motor neuron differentiation in both 
hESC- and iPSC-derived cells. Future studies are planned to investigate the effects of 
microneurotrophins and SK channel activators on the electrical excitability of these stem 
cell derived motor neurons.  
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